JP2018522571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522571A5 JP2018522571A5 JP2018506513A JP2018506513A JP2018522571A5 JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5 JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cancer
- domain
- hexameric protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204212P | 2015-08-12 | 2015-08-12 | |
| US62/204,212 | 2015-08-12 | ||
| US201662350447P | 2016-06-15 | 2016-06-15 | |
| US62/350,447 | 2016-06-15 | ||
| PCT/EP2016/069175 WO2017025610A1 (en) | 2015-08-12 | 2016-08-11 | Gitrl fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522571A JP2018522571A (ja) | 2018-08-16 |
| JP2018522571A5 true JP2018522571A5 (https=) | 2019-09-12 |
Family
ID=56740217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506513A Pending JP2018522571A (ja) | 2015-08-12 | 2016-08-11 | Ｇｉｔｒｌ融合タンパク質およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10428131B2 (https=) |
| EP (1) | EP3334758A1 (https=) |
| JP (1) | JP2018522571A (https=) |
| KR (1) | KR20180033588A (https=) |
| CN (1) | CN108026158A (https=) |
| AU (1) | AU2016306625A1 (https=) |
| BR (1) | BR112018002039A2 (https=) |
| CA (1) | CA2994346A1 (https=) |
| CL (1) | CL2018000358A1 (https=) |
| CO (1) | CO2018002450A2 (https=) |
| HK (2) | HK1250043A1 (https=) |
| IL (1) | IL257113A (https=) |
| MX (1) | MX2018001787A (https=) |
| RU (1) | RU2018108236A (https=) |
| TW (1) | TW201718632A (https=) |
| WO (1) | WO2017025610A1 (https=) |
| ZA (1) | ZA201801640B (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| WO2018178074A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| WO2018215506A1 (en) * | 2017-05-23 | 2018-11-29 | Université De Genève | Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| JP2020524694A (ja) | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| AU2018292618A1 (en) | 2017-06-27 | 2019-12-19 | Novartis Ag | Dosage regimens for anti-TIM-3 antibodies and uses thereof |
| CN111163798A (zh) | 2017-07-20 | 2020-05-15 | 诺华股份有限公司 | 用于抗lag-3抗体的给药方案及其用途 |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| TW201922291A (zh) | 2017-11-16 | 2019-06-16 | 瑞士商諾華公司 | 組合療法 |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| AR114552A1 (es) * | 2018-08-13 | 2020-09-16 | Inhibrx Inc | Polipéptidos de unión a ox40 y sus usos |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| CN113227138A (zh) | 2018-12-21 | 2021-08-06 | 诺华股份有限公司 | IL-1β结合抗体的用途 |
| BR112021011351A2 (pt) | 2018-12-21 | 2021-11-16 | Novartis Ag | Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| TW202128191A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Tim-3抑制劑及其用途 |
| CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| JP2023510393A (ja) | 2020-01-17 | 2023-03-13 | ノバルティス アーゲー | 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ |
| KR102647829B1 (ko) * | 2020-04-22 | 2024-03-14 | 포항공과대학교 산학협력단 | 삼량체를 형성하는 코로나-19 바이러스 (COVID-19, Coronavirus Disease 2019)의 재조합 스파이크 단백질 및 식물에서의 상기 재조합 스파이크 단백질의 대량 생산 방법과 이를 기반으로하는 백신조성물 제조 방법 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| US20230235007A1 (en) * | 2020-06-15 | 2023-07-27 | Ming-Che Shih | Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN113429488B (zh) * | 2021-07-14 | 2022-08-30 | 海正生物制药有限公司 | GITR/TGF-β双靶向融合蛋白及其用途 |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| ZA200509143B (en) * | 2003-05-23 | 2007-03-28 | Wyeth Corp | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| DK2650020T3 (en) * | 2005-05-06 | 2017-01-16 | Providence Health & Services - Oregon | Trimeric OX40 immunoglobulin fusion protein and methods for applications. |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| TWI476001B (zh) * | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| WO2015116178A1 (en) * | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| RU2016150096A (ru) | 2014-05-29 | 2018-07-02 | МЕДИММЬЮН, ЭлЭлСи | Белки слияния на основе ox40l и пути их применения |
-
2016
- 2016-08-11 CA CA2994346A patent/CA2994346A1/en not_active Abandoned
- 2016-08-11 TW TW105125874A patent/TW201718632A/zh unknown
- 2016-08-11 JP JP2018506513A patent/JP2018522571A/ja active Pending
- 2016-08-11 MX MX2018001787A patent/MX2018001787A/es unknown
- 2016-08-11 KR KR1020187006894A patent/KR20180033588A/ko not_active Withdrawn
- 2016-08-11 EP EP16753881.8A patent/EP3334758A1/en not_active Withdrawn
- 2016-08-11 WO PCT/EP2016/069175 patent/WO2017025610A1/en not_active Ceased
- 2016-08-11 BR BR112018002039A patent/BR112018002039A2/pt not_active Application Discontinuation
- 2016-08-11 RU RU2018108236A patent/RU2018108236A/ru not_active Application Discontinuation
- 2016-08-11 HK HK18109489.9A patent/HK1250043A1/zh unknown
- 2016-08-11 CN CN201680045052.8A patent/CN108026158A/zh active Pending
- 2016-08-11 US US15/234,551 patent/US10428131B2/en not_active Expired - Fee Related
- 2016-08-11 HK HK18109492.4A patent/HK1250044A1/zh unknown
- 2016-08-11 AU AU2016306625A patent/AU2016306625A1/en not_active Abandoned
-
2018
- 2018-01-23 IL IL257113A patent/IL257113A/en unknown
- 2018-02-08 CL CL2018000358A patent/CL2018000358A1/es unknown
- 2018-03-05 CO CONC2018/0002450A patent/CO2018002450A2/es unknown
- 2018-03-09 ZA ZA2018/01640A patent/ZA201801640B/en unknown
-
2019
- 2019-09-03 US US16/559,152 patent/US20200140510A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522571A5 (https=) | ||
| RU2018108236A (ru) | Слитые белки на основе gitrl и пути их применения | |
| US12173082B2 (en) | Bispecific polypeptides against CD137 | |
| US10774150B2 (en) | Polypeptides | |
| JP7411627B2 (ja) | Ｉｌｔ４と結合する抗体 | |
| AU2017299610B2 (en) | Multimeric CD40 binding molecules and uses thereof | |
| AU2015321546B2 (en) | Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof | |
| JP2021118754A (ja) | Ｃｄ３８に結合する抗体治療剤 | |
| CA3142738A1 (en) | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function | |
| US20190330374A1 (en) | Multimeric ox40 binding molecules and uses thereof | |
| RU2016150096A (ru) | Белки слияния на основе ox40l и пути их применения | |
| JP7128819B2 (ja) | Ａｄａｍ９結合分子、およびその使用方法 | |
| CN116333138A (zh) | Pd-1结合分子和其使用方法 | |
| KR20240095463A (ko) | 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 | |
| US20220073635A1 (en) | Novel polypeptides | |
| US11873348B2 (en) | Peptides | |
| Waight et al. | Harnessing co-stimulatory TNF receptors for cancer immunotherapy: current approaches and future opportunities | |
| EP4259645A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| CA3220027A1 (en) | Bispecific fc fusion proteins with spd-1 and il-15 | |
| HK40128201A (en) | Adam9-binding molecules, and methods of use thereof | |
| HK40004686B (en) | Novel bispecific polypeptides against cd137 | |
| HK1241895B (en) | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |